Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - March 27, 2025Idorsia Ltd (SIX: IDIA) today announced the publication of the Annual Report 2024 - consisting of the Business Report ...

Idorsia Pharmaceuticals has claimed FDA approval for aprocitentan as a treatment for resistant hypertension, becoming the first drug in the endothelin receptor antagonist class for that indication.

Daridorexant, Idorsia's dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...

"Idorsia’s Tryvio deal collapses, forcing company to find cash urgently" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site ...

The study, named A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia, is a ...

The agreement was signed concurrently with Nxera’s assignment of its option to these same rights from Idorsia Pharmaceuticals Ltd under its agreement in July 2023 to acquire Idorsia ...

The live webcast can be accessed from the Idorsia website www.idorsia.com. Dial-in procedure for analysts (audio only): Analysts who would like to ask questions are required to register in advance ...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 27, 2025Idorsia Ltd (SIX: IDIA) today announced the ...

Idorsia Ltd (SIX: IDIA) today announced the publication of “A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia” in the Journal of Sleep Research. The new ...

The live webcast can be accessed from the Idorsia website www.idorsia.com. Dial-in procedure for analysts (audio only): Analysts who would like to ask questions are required to register in advance of ...